See What HealthDay Can Do For You
Contact Us

More Otologic Symptoms, Hearing Loss for HIV-Infected

Odds of hearing loss up for HAART-naive patients, those receiving first-, second-line HAART

FRIDAY, March 6, 2015 (HealthDay News) -- Otologic symptoms and hearing loss are more common among patients with HIV than uninfected controls, according to a study published online March 5 in JAMA Otolaryngology -- Head & Neck Surgery.

Jean Valentin F. Fokouo, M.D., from the University of Yaoundé I in Cameroon, and colleagues examined the effect of HIV and highly-active antiretroviral treatment (HAART) on hearing function in a Cameroonian population. Data were included from 90 HIV-positive case patients (30 HART-naive patients, 30 patients receiving first-line HAART, and 30 receiving second-line HAART) and 90 HIV-negative controls. Participants were aged 15 to 49 years, with no history of hearing loss or treatment with a known ototoxic drug.

The researchers found that, compared with HIV-negative patients, HIV-positive patients had more otologic symptoms (41 versus 13; P = 0.04). Hearing loss was seen in 27.2 percent of the HIV-positive group versus 5.6 percent of the HIV-negative group (P = 0.04). The odds of hearing loss were higher among HIV-infected HAART-naive patients (right ear: odds ratio [OR], 6.7; left ear: OR, 6.2), patients receiving first-line HAART (right ear: OR, 5.6; left ear: OR, 12.5), and patients receiving second-line HAART (right ear: OR, 6.7; left ear: OR, 3.7), compared with HIV-negative individuals.

"Further studies are needed because controversy remains regarding the factors that lead to ear damage," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.